Contributions
Abstract: EP1447
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
The objectives of this study was to study the relationship between migraine and MS therapies. 782 MS patients were consecutively admitted. All patients filled out a detailed headache questionnaire and 754 patients were included. Of the total population of 754 MS patients recruited in our center, 515 (68%) reported headaches. Based on headache characteristics on evaluation, 202 (27%) were diagnosed with migraine [128 (17%) patients with migraine without aura, 52 (6.9%) patients with migraine with aura, 17 (2.3%) patients with probable migraine without aura, 5 (% 0.7) patients with chronic migraine]. One hundred and three patients (17%) gave a history of tension-type of headache and 198 (26.3%) patients described to have medical overuse headache. There were 12 (1.6%) patients with unclassified headache. During our study 558 MS patients (74%) were treated with interferon beta therapy/glatiramer acetate. 115 patients (15.3%) received fingolimod. 48 MS patients (6.4%) were treated with teriflunamide, and 33 MS patients (4.4%) received natalizumab. There was no statistical difference between medications and migraine. The mean age of onset of specific treatment for MS was 29.4 and there was a significant association between migraine and the age of onset of MS therapies. The mean age of onset of headaches was 27.4 years. When all headache groups were compared, the age of onset of headache was the earliest in the patients with migraine (mean 25,2). As regards the possible relationships between duration of the history of medication use and headaches, the incidence of migraine was higher in all headache patients. According to this result, the shorter duration of medication use the higher incidence of migraine. The mean value of total duration of medication use until migraine occurrence was 1.82 years. In migraine patients, the duration of medication use until the headache onset was the longest when compared to other headache groups. There was a statistically significant difference between migraine and concomitant symptoms (nausea, vomiting, phonophobia, and photophobia). The consultation rates for migraine in our MS patients were not rare and 78% of patients with migraine were seen by physicians due to headache complaints. In this study, migraine was more common than other headaches and the association between migraine and the age of onset of MS therapies, and also duration of medication use were significant.
Disclosure: nothing to disclose
Abstract: EP1447
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
The objectives of this study was to study the relationship between migraine and MS therapies. 782 MS patients were consecutively admitted. All patients filled out a detailed headache questionnaire and 754 patients were included. Of the total population of 754 MS patients recruited in our center, 515 (68%) reported headaches. Based on headache characteristics on evaluation, 202 (27%) were diagnosed with migraine [128 (17%) patients with migraine without aura, 52 (6.9%) patients with migraine with aura, 17 (2.3%) patients with probable migraine without aura, 5 (% 0.7) patients with chronic migraine]. One hundred and three patients (17%) gave a history of tension-type of headache and 198 (26.3%) patients described to have medical overuse headache. There were 12 (1.6%) patients with unclassified headache. During our study 558 MS patients (74%) were treated with interferon beta therapy/glatiramer acetate. 115 patients (15.3%) received fingolimod. 48 MS patients (6.4%) were treated with teriflunamide, and 33 MS patients (4.4%) received natalizumab. There was no statistical difference between medications and migraine. The mean age of onset of specific treatment for MS was 29.4 and there was a significant association between migraine and the age of onset of MS therapies. The mean age of onset of headaches was 27.4 years. When all headache groups were compared, the age of onset of headache was the earliest in the patients with migraine (mean 25,2). As regards the possible relationships between duration of the history of medication use and headaches, the incidence of migraine was higher in all headache patients. According to this result, the shorter duration of medication use the higher incidence of migraine. The mean value of total duration of medication use until migraine occurrence was 1.82 years. In migraine patients, the duration of medication use until the headache onset was the longest when compared to other headache groups. There was a statistically significant difference between migraine and concomitant symptoms (nausea, vomiting, phonophobia, and photophobia). The consultation rates for migraine in our MS patients were not rare and 78% of patients with migraine were seen by physicians due to headache complaints. In this study, migraine was more common than other headaches and the association between migraine and the age of onset of MS therapies, and also duration of medication use were significant.
Disclosure: nothing to disclose